Routine newborn screening (NBS) has revolutionized early detection of disease. However, traditional biochemical tests are limited in the range of symptoms that can be identified at birth. Next-generation sequencing is being investigated as a complementary screening tool. Reviews published in pediatric survey examines how next-generation sequencing can extend NBS from a single-disease assay to a genome-enabled multi-disease screening approach.
Each year, millions of newborns undergo routine screening as a preventive strategy to detect genetic disorders before symptoms appear. Newborn screening (NBS) programs have traditionally relied on biochemical markers to identify specific groups of treatable conditions and have achieved remarkable success at the population level. However, as researchers increasingly identify genetically driven diseases that manifest early in life, questions are being raised about whether existing screening frameworks are appropriate for the genomic era.
To fill this gap in early detection of genetic diseases, Dr. Zhelan Huang of Fudan University Children’s Hospital in China and Dr. Wenhao Zhou of Guangzhou Women’s and Children’s Medical Center examined the role of next-generation sequencing (NGS) in reshaping the NBS landscape. Their research is pediatric survey On January 6, 2026, we examined the transition from single-disease biochemical assays for NBS to a genome-enabled, multi-disease approach, while also delving into the challenges limiting the clinical implementation of genomic NBS (gNBS).
Dr. Chou explains:Traditional NBS methods are inherently limited by their dependence on measurable biochemical abnormalities. Although effective in diseases such as phenylketonuria and congenital hypothyroidism, many genetic diseases do not produce detectable metabolic signals during the neonatal period. As a result, affected infants appear healthy at birth, but develop symptoms after irreversible damage has already occurred.“Genetic screening therefore provides a direct strategy to detect disease risk at the earliest possible stage.
gNBS uses NGS technology to analyze DNA obtained from the same dried blood spots already collected for routine screening. Targeted gene panels, whole exome sequencing, and whole genome sequencing allow simultaneous assessment of multiple genes associated with inherited diseases. This genomic approach can significantly extend the benefits of NGS by identifying conditions that cannot be detected with traditional biochemical tests.
However, genomic screening introduces new complexities. One of the most important challenges is interpreting genetic variants of uncertain significance whose clinical significance remains unclear. Reporting such findings in a population-wide screening program may cause unnecessary anxiety to parents and raise ethical concerns. Therefore, gNBS requires careful selection of reportable genes and variants, with a particular focus on those that have produced clinically actionable results in childhood.
While traditional screening methods provide results within days, genome sequencing can take weeks. This delay limits its usefulness in situations where immediate intervention is required. Dr. Chou added:The main focus of the research is to reduce the turnaround time for genetic screening through a rapid whole-genome sequencing approach, which has already been applied to some critically ill infants. Although these approaches have not yet been used for routine population screening, continued efforts may expand their application in the future. ”
The main aspects that have been discussed since the beginning are the psychological and ethical aspects surrounding gNBS. Although many parents view genomic screening favorably, medical professionals tend to be more cautious, reflecting concerns about data interpretation, consent, and long-term storage of data. Another complex issue that arises is whether to report adult-onset symptoms or incidental findings, which highlights the need for a clear policy framework and access to genetic counseling support.
Dr. Chou says:With cost reductions, technological advances, and supportive policy frameworks, gNBS is expected to gradually integrate and even evolve into standardized tools for neonatal health management. ” When used in conjunction with traditional assays, it can help clarify ambiguous results and identify conditions that are beyond the detection limits of traditional methods.
Genomic screening has the potential to improve the identification and management of genetic diseases from birth, while technical, ethical, and logistical challenges continue to shape its implementation. gNBS has the potential to enable a more accurate and informed approach to neonatal care, extending the benefits of screening beyond early diagnosis and supporting long-term health planning.
sauce:
Reference magazines:
Huang, Z. & Zhou, W. (2026). Next-generation sequencing in newborn screening: current status, challenges, and future prospects. Pediatric research. DOI: 10.1002/ped4.70030. https://onlinelibrary.wiley.com/doi/10.1002/ped4.70030
